Bayer and its subsidiary AskBio touted early data from a small, early trial evaluating the safety of its gene therapy for Parkinson’s disease and announced plans for a Phase II study Thursday morning. The Phase Ib trial hit its primary endpoint, which was to show the safety of a one-time delivery of the gene therapy, dubbed AB-1005, into 11 patients split between two cohorts. Six patients had mild stage Parkinson’s, while five had moderate stage. Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
BECOME A PREMIUM SUBSCRIBER